WO2008138348A8 - Preparation of complexed lactalbumin - Google Patents

Preparation of complexed lactalbumin Download PDF

Info

Publication number
WO2008138348A8
WO2008138348A8 PCT/DK2008/050105 DK2008050105W WO2008138348A8 WO 2008138348 A8 WO2008138348 A8 WO 2008138348A8 DK 2008050105 W DK2008050105 W DK 2008050105W WO 2008138348 A8 WO2008138348 A8 WO 2008138348A8
Authority
WO
WIPO (PCT)
Prior art keywords
lactalbumin
alpha
lipid
fatty acid
complex
Prior art date
Application number
PCT/DK2008/050105
Other languages
French (fr)
Other versions
WO2008138348A1 (en
Inventor
Emmanuel Ruffet
Dianne Falk Rasmussen
Birgit Nielsen
Finn Matthiesen
Original Assignee
Nya Hamlet Pharma Ab
Emmanuel Ruffet
Dianne Falk Rasmussen
Birgit Nielsen
Finn Matthiesen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nya Hamlet Pharma Ab, Emmanuel Ruffet, Dianne Falk Rasmussen, Birgit Nielsen, Finn Matthiesen filed Critical Nya Hamlet Pharma Ab
Publication of WO2008138348A1 publication Critical patent/WO2008138348A1/en
Publication of WO2008138348A8 publication Critical patent/WO2008138348A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a method for the preparation of a biologically active alpha-lactalbumin complex comprising alpha-lactalbumin and a fatty acid or a lipid said method comprising the steps of: obtaining an alpha-lactalbumin composition; conversion of said alpha-lactalbumin to alpha-lactalbumin complex by mixing alpha- lactalbumin or a functional homologue thereof and a fatty acid or a lipid in the absence of an ion exchange medium, and subsequently exposing the mixture to an ion exchange medium. The active alpha-lactalbumin complex comprising alpha-lactalbumin and a fatty acid or a lipid are suitable for use in the manufacture of medicaments for use in therapy. Medicaments, comprising monomeric LAC are for use in the treatment of bladder cancer, papiloma and actinic keratosis.
PCT/DK2008/050105 2007-05-09 2008-05-09 Preparation of complexed lactalbumin WO2008138348A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92430907P 2007-05-09 2007-05-09
DKPA200700693 2007-05-09
DKPA200700693 2007-05-09
US60/924,309 2007-05-09

Publications (2)

Publication Number Publication Date
WO2008138348A1 WO2008138348A1 (en) 2008-11-20
WO2008138348A8 true WO2008138348A8 (en) 2009-07-30

Family

ID=39717634

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2008/050105 WO2008138348A1 (en) 2007-05-09 2008-05-09 Preparation of complexed lactalbumin

Country Status (1)

Country Link
WO (1) WO2008138348A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009135494A2 (en) * 2008-05-09 2009-11-12 Nya Hamlet Pharma Ab Alpha-lactalbumin composition for the treatment of actinic keratosis
WO2010079362A1 (en) 2009-01-09 2010-07-15 Hamlet Pharma Ab Complex and production process
WO2010131237A1 (en) 2009-05-13 2010-11-18 Agriculture And Food Development Authority (Teagasc) A process for producing a biologically active globular protein complex
PL2643010T3 (en) 2010-11-24 2017-05-31 Hamlet Pharma Ab Biologically active complex and its preparation
HUE038910T2 (en) 2012-08-09 2018-12-28 Hamlet Pharma Ab Prophylactic and nutraceutical therapy
CN103134881A (en) * 2013-02-01 2013-06-05 浙江省疾病预防控制中心 Cattle 2, 2-bipyridine-lactalbumin quantitative detection reagent box and application thereof
CN103642895B (en) * 2013-12-06 2015-12-30 贝因美婴童食品股份有限公司 A kind of method of detection by quantitative people ALA content and test kit
IT201800003557A1 (en) 2018-03-14 2019-09-14 Kolfarma S R L Pharmaceutical preparation or food supplement based on alpha-lactalbumin
CN113827707B (en) * 2021-09-30 2023-12-05 北京大学 Use of a-lactalbumin for inhibiting coronaviruses
WO2024075003A1 (en) 2022-10-03 2024-04-11 Linnane Pharma Ab A complex comprising a alpha-lactalbumin and a fatty acid or lipid for use in the treatment or prevention of cancer
GB202303177D0 (en) 2023-03-03 2023-04-19 Linnane Pharma Ab Method of predicting response to treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1032596B1 (en) * 1997-11-21 2007-05-02 Nya Hamlet Pharma AB Lactalbumin production process
US20080039381A1 (en) * 2004-02-26 2008-02-14 Catharina Svanborg Lactalbumin for Inhibiting Angiogenesis
US20100029557A1 (en) * 2006-11-17 2010-02-04 Jens Sigh Alpha-lactalbumin composition

Also Published As

Publication number Publication date
WO2008138348A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
WO2008138348A8 (en) Preparation of complexed lactalbumin
WO2008058547A3 (en) Alpha-lactalbumin composition
JP2010270124A5 (en)
IL190400A (en) Physically and chemically stable water soluble amphiphilic polymer-pdgf complexes, method for preparing the same, therapeutic compositions comprising them and uses thereof in the preparation of topical compositions for the treatment of ulcers
WO2009067605A3 (en) Preparations, methods and kits useful for treatment of cough
MY164274A (en) Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
WO2008137758A3 (en) Amino acid lipids and uses thereof
TW200635924A (en) Chemical compounds
WO2006037342A3 (en) Controlled release pharmaceutical compositions comprising a fumaric acid ester
AR042340A1 (en) CONTROLLED RELEASE OF AN ACTIVE SUBSTANCE TO A GREAT ENVIRONMENT
WO2007128923A3 (en) Method for the preparation of a biocompatible gel with controlled release of one or more active ingredients with low solubility in water, gels thus obtained and their use
IL198314A (en) Quinuclidine derivatives of (hetero) arylcycloheptanecarboxylic acid, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for therapy
WO2007075255B1 (en) Mastic gum composition for use as a dietary supplement in humans and animals
SI1730147T1 (en) SUBSTITUTED 1,4,8-TRIAZASPIRO?á4,5?åDECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY
UA97090C2 (en) Use of salt, addition compound or complex compound of guanidinoacetic acid as nutritional supplement
EP2350058A4 (en) Novel method and application of unsymmetrically meso-substituted porphyrins and chlorins for pdt
WO2007105015A3 (en) DERIVATIVES OF 18ß-GLYCYRRHETINIC ACID
CN102440386A (en) Full-composite human body antioxidant
CY1109460T1 (en) Substituted 5,6,7,8-tetrahydro-imidazo [1,2-A] -pyridin-2-ylamine compounds and their use in the manufacture of medicaments
ATE452120T1 (en) FATTY ACID BENZENEDIOL DERIVATIVES AND PRODUCTION AND USE PROCESSES THEREOF
WO2011047837A3 (en) Melt-granulated cinacalcet
CN102614111A (en) Glucosamine gel and preparation method thereof
WO2007029121A3 (en) Novel cyclopent-2-en-1-one derivatives which are ppar receptor modulators, and use thereof in pharmaceutical or cosmetic compositions
WO2008051527A3 (en) Sustained release of agents for localized pain management
BRPI0715609A2 (en) COMPOUND, USE OF A COMPOUND, METHODS TO PRODUCE AN ANTIPROLIFERATIVE EFFECT ON A HOT BLOOD ANIMAL, AND TO TREAT DISEASE IN A HOT BLOOD ANIMAL, AND PHARMACEUTICAL COMPOSITION

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08734560

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08734560

Country of ref document: EP

Kind code of ref document: A1